- Willow Biosciences (TSX: WLLW, OTCQB: CANSF) announced key approvals from its 2025 annual general and special meeting.
- Strong shareholder support for board elections, sale of Epimeron USA, and potential company name change.
- Low shareholder participation rate of 40.88%.
Willow Biosciences Inc. (TSX: WLLW, OTCQB: CANSF) conducted its annual general and special meeting on April 25, 2025, reporting shareholder participation of 40.88%, with 59,214,893 common shares represented.
The company reported strong investor support for the election of five directors. The elected directors received an approval rating ranging from 84.5% to 88.4%. The directors are Dr. Chris Savile, Dr. Jim Lalonde, Donald Archibald, Raffi Asadorian, and Al Foreman.
Shareholders also approved the appointment of KPMG LLP as auditor for the coming year, garnering 87.6% approval. The proposed sale of Willow's wholly-owned subsidiary, Epimeron USA, received 88.4% support, indicating robust backing for this strategic move.
Furthermore, a significant change on the horizon for Willow Biosciences is the potential name change to "2482118 Alberta Ltd.", receiving 82.5% shareholder approval. This authorization suggests possible corporate rebranding or a strategic restructuring move.
Despite the substantial approvals, the meeting witnessed relatively low shareholder engagement, with only 40.88% participation in the vote.
